Helping You Find Full Text Journal Articles

Search Results:

Author: Sandy Balkaran (4)


Jan
2018

The Epstein-Barr virus nuclear antigen leader protein (EBNA-LP) acts as a co-activator of EBNA-2, a transcriptional activator essential for Epstein-Barr virus (EBV)-induced B-cell transformation. Burkitt's lymphoma (BL) cells harboring a mutant EBV strain that lacks both the EBNA-2 gene and 3' exons of EBNA-LP express Y1Y2-truncated isoforms of EBNA-LP (tEBNA-LP) and better resist apoptosis than if infected with the wild-type virus. In such BL cells, tEBNA-LP interacts with the protein phosphatase 2A (PP2A) catalytic subunit (PP2A C), and this interaction likely plays a role in resistance to apoptosis.

View Full Text PDF Listings View primary source full text article PDFs.

Jun
2013

We observed an increased rate of Pseudomonas aeruginosa bacteremia in our hematology unit in 2004-2007 without an identified environmental source.
We conducted a matched case-control study to investigate factors associated with P aeruginosa bacteremia in patients with hematologic malignancies.
Forty-two episodes of P aeruginosa bacteremia were identified.

View Full Text PDF Listings View primary source full text article PDFs.

Mar
2009

Nucleoside Analogues (NA) are considered as appropriate agents in the treatment of Waldenström's Macroglobulinemia (WM). There are sporadic reports on increased incidence of transformation to high grade non-Hodgkin lymphoma (transformation to NHL) and development of therapy related-myelodysplasia/acute leukemia (t-MDS/AML) among WM patients treated with NA. Several studies have been conducted in Europe and in the United States to retrospectively examine the incidence of such events in WM patients.

View Full Text PDF Listings View primary source full text article PDFs.

Apr
2009

Despite advances in therapy, Waldenstrom's macroglobulinemia (WM) remains incurable. Guidelines on therapeutic alternatives in WM recommended the use of alkylating agents, rituximab, nucleoside analogues and anthracyclins either in first line or at relapse and in combination in fit patients. While the overall response rates of combination regimens reached up to 80 - 90% in some studies, the complete response rate is low, no greater than 10 - 20%; and the disease-related median survival for symptomatic patients is approximately 6 years.

View Full Text PDF Listings View primary source full text article PDFs.

Back to top